Long-term Survival of a Hepatocellular Carcinoma Patient Treated by Korean Medicine Combined with Western Therapy: a Case Report |
Kang, Ji-Young
(Department of Internal Medicine, College of Korean Medicine, Daejeon University)
Kim, Jun-Young (Department of Internal Medicine, College of Korean Medicine, Daejeon University) Son, Chang-Gue (Department of Internal Medicine, College of Korean Medicine, Daejeon University) Cho, Jung-Hyo (Department of Internal Medicine, College of Korean Medicine, Daejeon University) |
1 | Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol. 2005;100(9):1995-2004. DOI ScienceOn |
2 | Pawarode A, Voravud N, Striuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol. 1998; 21:386-391. DOI ScienceOn |
3 | Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines in Japan. World J Gastroenterol. 2006;12(5):828-829. DOI |
4 | Park HY, Cho JH, Son CG, Cho CK. Adenoid Cystic Carcinoma of the submandible in a 56-year-old woman. J Korean Orient Int Med. 2005:26(4):941-945. |
5 | Kim KS. Yoo HS. Jung TY. Lee YW. Cho CK. Case series of advanced or metastatic gallbladder cancer patients treated with HangAm-Dan. J Korean Orient Int Med. 2010:31(3):667-74. |
6 | Yoo HS, Kim SH, Lee YW, Cho CK, Lee KH. Two Cases of Endometrial Cancer Treated with Palliative Herbal Medication Hangam-dan (HAD). J Korean Oriental Med. 2007:8(4):176-180. |
7 | Garrison RN, Kaelin LD, Galloway RH, Heuser LS. Malignant ascites. Clinical and experimental observations. Ann Surg. 1986;203:644-651. DOI |
8 | Kim SW, Lee SH, Roh BJ, Kim JC, Park SS, Lee DH. Prognostic factors affecting survival rate in patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization. CMH. 2000;6(3):311-320. |
9 | Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80:827-841. DOI |
10 | EL-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002;35:S72-S78. DOI ScienceOn |
11 | Jordi B, Morris S. Management of Hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. DOI ScienceOn |
12 | Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, et al. Hepatectomy for hepatocellular carcinoma: Toward zero hospital deaths. Ann Surg. 1999;229:322-30. DOI ScienceOn |
13 | Nagasue N, Uchida M, Makino Y, Takemoto Y, Yamanoi A, Hayashi T, et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma.Gastroenterology. 1993;105:488-494. DOI |
14 | Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390. DOI ScienceOn |